Jubilant Pharmova share price has zoomed 5% and is presently trading at Rs 945.0.
Meanwhile, the BSE HEALTHCARE index is at 42,383.7 (up 0.5%).
Among the top gainers in the BSE HEALTHCARE index today are Pfizer (up 2.4%) and ALKEM LABORATORIES (up 2.2%).
ALEMBIC PHARMA (down 1.2%) and MAX HEALTHCARE INSTITUTE (down 0.7%) are among the top losers today.
Over the last one year, Jubilant Pharmova has moved up from Rs 462.4 to Rs 945.0, registering a gain of Rs 482.7 (up 104.4%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,099.5 to 42,383.7, registering a gain of 50.8% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 131.5%), Glenmark Pharma (up 126.3%) and SUVEN PHARMACEUTICALS (up 106.8%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 81,670.8 .
The top losers among the BSE Sensex today are Bajaj Finserv (down 1.2%) and JSW Steel (down 1.2%). The most traded stocks in the BSE Sensex are Tata Steel and ITC.
In the meantime, NSE Nifty is at 24,998.4 (down 0.1%). BPCL and Bajaj Finserv are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,433.3 to 81,670.8, registering a gain of 16,237.5 points (up 24.8%).
Jubilant Pharmova net profit grew 6410.8% YoY to Rs 4,818 million for the quarter ended June 2024, compared to a profit of Rs 74 million a year ago. Net sales rose 9.1% to Rs 17,317 million during the period as against Rs 15,869 million in April-June 2023.
For the year ended March 2024, Jubilant Pharmova reported 212.0% increase in net profit to Rs 727 million compared to net loss of Rs 649 million during FY23. Revenue of the company grew 6.7% to Rs 67,029 million during FY24.
The current Price to earnings ratio of Jubilant Pharmova, based on rolling 12 month earnings, stands at 28.8.
Equitymaster requests your view! Post a comment on "Jubilant Pharmova Gains 5%; BSE HEALTHCARE Index Up 0.5%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!